文献速递临床试验与 GCP

头盔式家用低水平光疗设备对化疗所致脱发的影响:一项随机对照试验的研究方案

The effect of a helmet type, home-use low-level light therapy device for chemotherapy-induced alopecia: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-12-05

本研究为随机对照试验方案,计划纳入106例乳腺癌化疗患者,随机分为低水平光疗组与对照组,光疗组4周内接受12次干预,对照组不干预但密切监测。主要结局为第4周末目标区域毛发计数较基线的变化,采用phototrichogram(Sentra头皮分析仪)测量,旨在评估低水平光疗预防化疗所致脱发的疗效。

要点

  • 头皮冷却为目前唯一经验证的化疗脱发预防方法,但成功率无保证。
  • 低水平光疗已被临床证明可抑制雄激素性脱发进展。
  • 本研究采用随机对照设计,评估头盔式家用低水平光疗对乳腺癌化疗脱发的预防效果。

核心结论

  • 本研究旨在确定低水平光疗对乳腺癌患者化疗所致脱发的预防疗效,并称可改善癌症患者生活质量并提供临床证据。

研究设计与样本

  • 随机对照试验,纳入106例符合条件的乳腺癌患者,化疗后随机分入低水平光疗组与对照组。
  • 低水平光疗组在4周内接受12次干预,对照组不干预但密切监测。
  • 主要结局为第4周末目标区域毛发计数较基线的变化,采用phototrichogram(Sentra头皮分析仪)测量。

主要发现

  • 次要结局包括第1、2、3周末毛发计数变化及第1、2、3、4周末毛发宽度变化,采用phototrichogram测量。
  • 次要结局还包括第4周末采用问卷测量的化疗所致脱发相关痛苦、生活质量及自尊的变化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia is one of the most common adverse effects of chemotherapy. It reduces the patient's self-esteem and quality of life and the effect of therapy. Scalp cooling is the only verified current method for prevention but success is not guaranteed, particularly after receiving anthracycline-based combinations. Low-level light therapy has been clinically proven to inhibit the progress of androgenic alopecia. A previous study using human subjects shows limited benefits for low-level light therapy for patients who suffer chemotherapy-induced alopecia but an increase in the number of probes and the optimization of light sources may improve the efficacy. This study determines the efficacy of low-level light therapy for the prevention of chemotherapy-induced hair loss for patients with breast cancer using a randomized controlled trial. METHODS: One hundred six eligible breast cancer patients were randomly distributed into a low-level light therapy group and a control group, after receiving chemotherapy. Subjects in the low-level light therapy group received 12 courses of intervention within 4 weeks. Subjects in the control group received no intervention but were closely monitored. The primary outcome is measured as the difference in the hair count in a target area between the baseline and at the end of week 4, as measured using a phototrichogram (Sentra scalp analyzer). The secondary outcomes include the change in hair count at the end of week 1, week 2, and week 3 and hair width at the end of week 1, week 2, week 3, and week 4, as measured using a phototrichogram, and the change in distress, the quality of life, and self-esteem due to chemotherapy-induced alopecia, at the end of week 4, as measured using a questionnaire. DISCUSSION: This study improves cancer patients' quality of life and provides clinical evidence. TRIAL REGISTRATION: Registered at ClinicalTrials.gov- NCT05397457 on 1 June 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wu CX, Li CH, Shiao YH, et al. The effect of a helmet type, home-use low-level light therapy device for chemotherapy-induced alopecia: study protocol for a randomized controlled trial. Trials. 2023. PMID: 38053197. doi:10.1186/s13063-023-07823-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。